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          Table S1. Disaccharide compositions of the chemically-modified heparin derivatives*  
 
Disaccharide standard 
          D1                   D2                   D3                   D4                       D5                      D6                              D7                       D8 
∆UA-GlcNAc ∆UA-GlcNAc(6S) ∆UA-GlcNS ∆UA-GlcNS(6S) ∆UA(2S)-GlcNS ∆UA(2S)-GlcNS(6S) ∆UA(2S)-GlcNAc ∆UA(2S)-GlcNAc(6S)   % 
_____________________________________________________________________________________________________________ 
 
A       6.8       -                3.4        13.4                  7.0                67.4                -                         2.0                 100 
B      14.2     7               -          -                        -                         3.5                 -                         75.3               100           
C      7.1       -               13.7       79.2                   -                          -                    0                         0                   100 
D      15.5      -               43.2      7.0                      34.3                     -                    -                          -                   100 
E      14.4     62.9           3.4       19.3                    -                          -                    -                          -                   100 
F      55.8      7.7               -        -                   -                -                 34.8                    1.7                100  
G      19.1       -              79.1       -                   -              1.8                          -                          -                   100 
H      99        -              -      -                  -               -                          -                         1.0                100 
                                                                                                                                                                    
 
* The modified heparin derivatives were exhaustively digested with a mixture of 
heparitinases I, II and III to their constituent disaccharides (here denoted D1 to D8). The 
resulting component disaccharides were separated by strong-anion exchange HPLC (Propac 
PA-1 column, Dionex UK) and quantified (A232) with reference to authentic standards [1]. 
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Table S2. 1H and 13C NMR chemical shift values for the chemically-modified heparin 
derivatives* 
   Glucosamine    Iduronate 
 
Polysaccharide A-1     A-2   A-3   A-4     A-5    A-6     I-1     I-2     I-3     I-4     I-5    
 
A    99.5   60.7   72.5   78.8   72.0   69.2  102.1 78.9  72.1  79.0  72.3        
                        5.42   3.31   3.69   3.79   4.05   4.30-4.42           5.23   4.37  4.22  4.14  4.82 
 
B          96.6  56.2  73.0  79.3  72.3  69.6  102.2  76.8  67.3  74.2  70.8 
         5.15  4.03  3.76  3.78  4.04  4.31-4.37  5.20    4.37  4.31  4.08   4.91 
 
C        98.1  60.3  72.4  80.1  71.5  68.7  104.6  71.1  70.4  77.2  71.2 
         5.34  3.24  3.65  3.71  4.02  4.36  4.23            5.04    3.78  4.12  4.08  4.84  
 
D    100.0  60.8  72.4  80.5  73.8  62.6  102.0  77.6  70.7  78.7  71.4 
  5.31    3.27  3.71  3.70  3.89  3.86-3.88  5.26    4.35  4.25  4.06  4.84   
 
E  97.1  56.2  72.5  79.6  71.8  68.8  104.6  72.0  71.4  77.0  71.9 
  5.18  4.00  3.78  3.79  4.08  4.37-4.26  5.01    3.75  3.42  4.10  4.78  
 
F  96.8  56.6  72.9  80.6  74.2  62.9  102.3  76.6  67.1  74.1  70.6 
  5.14  4.03  3.79  3.76  3.91  3.87-3.92  5.26    4.37  4.28  4.07  4.91  
 
G  98.2  60.5  72.5  80.2  73.5  62.4  104.3  72.2  71.5  77.8  72.2 
  5.39  3.26  3.67  3.72  3.87  3.84-3.88  4.95    3.74  4.11  4.08  4.77   
 
H  97.1  56.2  72.3  79.6  73.7  62.3  104.3  72.5  72.2  77.3  72.6 
  5.18  3.97  3.76  3.74  3.89  3.85-3.88  4.92    3.69  3.89  4.07  4.73 
 
 
* The derivatives were characterised by 1H and 13C NMR to confirm their structure. NMR 
spectra were recorded in D2O at 40°C on a 400 MHz instrument. Assignment was by a 
combination of COSY, TOCSY, HMBC two-dimensional spectra. 13C spectra were recorded 
on 150 mg samples of the polysaccharide. Chemical shift values were recorded relative to 
trimethylsilyl propionate as reference standard at 40°C. The 1H chemical shift values quoted 
for position-6 of glucosamine residues (A-6) are intervals. Signals from the carbonyl group of 
iduronate and acetyl CH3 groups of N-acetylated glucosamine derivatives are not shown. The 
1H chemical shift values quoted for position-6 of glucosamine residues (A-6) are intervals. 
Signals from the carbonyl group of iduronate and acetyl CH3 groups of N-acetylated 
glucosamine derivatives are not shown. 
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Table S3. Chemically-modified heparin derivatives, sub-fractions and their structures  
Modified 
derivatives 
 Structural  
Modification
Molecular weight 
(kDa) 
    
C 2-de-O-sulfated I2OHa  
C1  I2OH  >7000 
C2  I2OH   7000-3000 
C3  I2OH  <3000 
D 6-de-O-sulfated A6OHb  
D1  A6OH   >7000 
D2  A6OH  7000-3000 
D3  A6OH <3000 
E 2-de-O-sulfated, N-acetylated I2OH, NAc  
E1  I2OH, NAc  >7000 
E2  I2OH, NAc  7000-3000 
E3  I2OH, NAc  <3000 
F 6-de-O-sulfated, N-acetylated A6OH, NAc  
F1  A6OH, NAc  >7000 
F2  A6OH, NAc  7000-3000 
F3  A6OH, NAc  <3000 
G 2,6-de-O-sulfated I2OH, A6OH  
G1  I2OH, A6OH  >7000 
G2  I2OH, A6OH  7000-3000 
G3  I2OH, A6OH  <3000 
H 2,6-de-O-sulfated, N-acetylated I2OH, A6OH, NAc   
H1  I2OH, A6OH, NAc  >7000 
H2  I2OH, A6OH, NAc  7000-3000 
H3  I2OH, A6OH, NAc  <3000 
aI=Iduronic acid; bA= glucosamine     
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Table S4. No detectable cytotoxic effect of the heparin derivatives on human cancer 
(ACA19+ and SW620) or endothelial (HUVEC) cells*  
 
Compound 
(100ug/ml) 
LDH 
(SW620 cells) 
LDH 
(ACA19+ cells) 
LDH 
(HUVEC cells) 
Heparin NDIa NDI NDI 
E  NDI NDI NDI 
E3 NDI NDI NDI 
F NDI NDI NDI 
F3 NDI NDI NDI 
aNDI: no detectable increase of cellular LDH release in comparison to the non-treated control 
cells after 48 hr compound exposure  
 
* Sub-confluent SW620, ACA19+ or HUVEC cells in 96-well plates were incubated at 37oC 
for 48 hours with 100 µg/ml of heparin or heparin derives.  The medium was removed and 
the amount of lactate dehydrogenase present was determined using a LDH-Cytotoxicity 
Assay Kit II.  Cells treated overnight without or with 1 µM staurosporine were used as 
negative and positive controls respectfully. 
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Figure S1: Sub-fractionation of the modified heparin derivatives. A: E, F and G were 
subfractionated on a Sephadex G-100 column (26mm x 1000 mm) in 0.5M ammonium 
bicarbonate on an AKTA Purifier 10 (GE Life Sciences).  Elution was monitored by 
absorbance at 232 nm.  Fractions corresponding to <7000 kDa, ~3000-7000 kDa and <3000 
kDa were pooled and freeze dried.  Size fractions were determined by calibrating the column 
using dextran standards as indicated in panel A, and were consistent with previously 
published calibrations for Sephadex G-100 [3]. The large peak in the <3000 fraction was due 
to residual copper from the chemical depolymerisation, which was subsequently removed 
using HiTrap desalting columns (B). The intermediate fractions (~3000-7000 Da) were also 
desalted using the same method. B: Desalting of fractions. The <3000 kDa fractions of 
heparin-derived polysaccharides E, F and G were desalted to remove residual copper using 
HiTrap desalting columns (2 x 5 ml) run in HPLC-grade water.  Elution was monitored by 
absorbance at 254 nm.  Saccharides elute in the V0 (at 6 minutes) while copper elutes in the 
VT (at 20 minutes). Fractions corresponding to the saccharides were collected, pooled and 
freeze dried. 
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Figure S2: Effects of heparin derivatives (40 µg/ml) and their sub-fractions on galectin-3 
binding to asialo-fetuin compared to standard heparin (40 µg/ml) and the known galectin-3 
inhibitor lactose (40 µg/ml) assessed by galectin-3 ELISA. 
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Figure S3. None of the potent galectin-3 binding inhibitory heparin derivatives (E, E3, F, F3, 
100µg/ml) shows inhibition of galectin-1 (A), -4 (B) or -8 (C) binding to TF-expressing 
asialo fetuin (ASF) when assessed by galectin ELISA.   
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Figure S4: Animal body weights of Balb/c nude mice during the course of experiments to 
assess the effects of modified heparin derivatives on galectin-3 mediated metastasis of human 
melanoma ACA19+ (A) and colon cancer SW620 (B) cells. The body weights of mice were 
measured weekly throughout and mice were sacrificed at 5 weeks (ACA19+) or 6 weeks 
following tumour cell injection (n=4 for ACA19+ and n=6 for SW620).  
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Figure S5. Effect of modified heparin derivatives on VEGF-induced angiogenesis in vivo in 
the chick chorioallantoic membrane (CAM) assay. Methyl-cellulose pellets (2mm diameter) 
were prepared containing either no or 100 ng of VEGF165, in the presence or absence of 10 
or 50µg of heparin derivative E or F. Samples were applied in the CAM assay on day 8 and 
the effects measured on day 10, as described previously [4]. Statistical analysis was 
performed using the Mann–Whitney U-test (*p<0.05).  Modified heparin derivatives show 
inhibition of angiogenesis in the presence of VEGF. The compounds alone did not produce 
any effects on angiogenesis in the absence of VEGF (data not shown). 
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Figure S6: NMR analysis of galectin-3 interaction with lactose and the modified heparin 
derivatives. 1H-15N spectra of Gal-3C in the absence (black), or presence of lactose (red), E3 
(green) and F3 (blue) in Gal-3C:ligand ratio of 1:20. Several 1H-15N HSQC cross-peaks show 
marked chemical shift changes, identifying residues involved in Gal-3C-ligand interaction 
when compared to Gal-3C alone. 
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